Protein Degradation Conferences
With 19 new drugs entering the clinic and 185 new degrader developers emerging in 2024 alone, and the field waiting with bated breadth for the first targeted protein degrader expected to gain commercial approval in 2025, the induced proximity field continues to experience rapid growth, reflecting the potential of these modalities to target the previously undruggable.
Our mission is to supercharge the development and approval of first- and best-in-class selective, safe and clinically efficacious degraders and proximity-based drugs for patients in need.